Pakistan launches phase-III clinical trial of Chinese vaccine
After flattening the virus curve, the public health strategy is aimed at slowing down the spread of the COVID-19 pandemic and the launching of the phase III trials for the Chinese-made vaccine is a party of it.
He said a total of 40,000 people will participate in this trial in seven countries, of which 8 to 10, 000 will be Pakistani.
Just launched the phase 3 trials for a Covid19 vaccine in Pakistan. Vaccine has been developed by a chinese company. A total of 40,000 people will participate in this trial in 7 countries, of which 8 to 10, 000 will be Pakistani. Initial results expected in 4 to 6 months— Asad Umar (@Asad_Umar) September 22, 2020
As per the statement issued by National Command and Control Center (NCOC) after a meeting chaired by Planning Minister Asad Umar held Tuesday in Islamabad, “The third clinical trial of corona vaccine has started in Pakistan, the first and second clinical trials of NCOC corona vaccine were conducted in China. The third phase of clinical trial of coronavirus vaccine is a public and private partnership venture.”
CGTN, China Global Television Network, also reported that China is conducting clinical trials of 11 COVID-19 vaccines, four of which have entered phase three trials. This was said by Wang Zhigang, Chinese Minister of Science and Technology, at the Global Science and Life Health Forum in Beijing.
Planning, Development and Special Initiatives Minister Asad Umar said that 40,000 people will participate in the trial, which is being held in seven countries across the world. Around 8,000 to 10,000 of these will be from Pakistan, he said.
Addressing a press conference alongside NIH Executive Director Maj Gen Aamer Ikram Islamabad after the NCOC meeting, Special Assistant to the Prime Minister on Health Dr Faisal Sultan termed the trial an important development in which Pakistanis would also take part.
Maj Gen Ikram said it was an honour for the country that it was participating in the phase III trial of a vaccine for the first time. "The entire world is looking towards a vaccine right now. There are seven vaccines for which trials are being conducted — three of them developed in China. This CanSino vaccine is based on recombinant technology in which an adino-vector is made deficient. The virus vector and cell culture have been procured from Canada," he said.
He added that the technology for the CanSino vaccine was similar to that of the Oxford vaccine being developed by AstraZeneca. A chimpanzee adino-vector was used in the AstraZeneca vaccine while a human adino-vector was used for this vaccine, he disclosed.
He said phase III trial was the biggest and most difficult stage. "The NIH has accepted this challenge and we are grateful to the patronage of the NCOC and the Ministry of Health."
A medical examination of the volunteers would be carried out after which the vaccine would be administered to them. Ikram added that the NIH would follow up with them for 12 months but the results of the vaccine would be expected in three months.
The vaccine would be available in the market in five to six months once its results were analysed and it was approved, said Ikram. "This is the vaccine that has already been approved and is being administered to army officials and policemen in China. Therefore, its safety is ensured," he concluded.